The properties of a synthetically produced peptide composed of the same primary structure of 18 amino acids described for human Escherichia coli heatstable enterotoxin were compared with those of purified heat-stable toxin obtained by bacterial growth. The dosage required to evoke fluid secretion in the suckling mouse and rat ligated ileal loop assays was the same for both toxins. The antigenicity of the two toxins was similar when assayed by enzyme-linked immunosorbent assay with hyperimmune antiserum to either toxin. The secretory effect of the two toxins in the suckling mouse assay was seroneutralized by the same dilutions of hyperimmune antiserum to either toxin. Immunization of rats with the synthetic toxin coupled to a large-molecular-weight carrier raised serum and mucosal antitoxin responses which provided protection against challenge with either the synthetic or biological toxin as well as with viable heat-stable enterotoxin-producing organisms. These observations indicate that synthetically produced heat-stable toxin has the same properties as the toxin derived by bacterial culture. The availability of the more readily made synthetic form of heat-stable toxin should facilitate the production of a vaccine based on cross-linking this toxin with either the heat-labile toxin or its nontoxic B subunit.
Acute diarrheal disease caused by enterotoxigenic strains of Escherichia coli (ETEC) is mediated by the release of two enterotoxins, either singly or together. The large-molecularweight, antigenic heat-labile toxin (LT) has been purified to homogeneity, and its subunit structure has been characterized as five B subunits which attach the holotoxin to specific GM, ganglioside receptors on the mucosal surface and a single A subunit which stimulates intracellular adenylate cyclase activity, thus evoking fluid and electrolyte secretion (4) (5) (6) 28) . The low-molecular-weight heat-stable toxin (ST) produced by ETEC strains of human or porcine origin has also recently been purified (1, 17, 22, 25, 31, 32) . These toxin preparations have a high content of half-cystine (1, 17, 31), cause secretion by stimulating guanylate cyclase (11) , and are haptenic, as evidenced by their capacity to raise an antitoxin response in animals immunized with the toxin coupled to a large-molecular-weight carrier (8, 12, 18) .
ST purified to homogeneity from human E.
coli LT-/ST' strain 18D (042:H47) has an estimated molecular weight of 1,972 and consists of 10 different amino acids arranged in a sequence of 18 amino acids (31) whose primary structure was shown by Chan and Giannella to be AsnThr-Phe-Tyr-Cys-Cys-Glu-Leu-Cys-Cys-TyrPro-Ala-Cys-Ala-Gly-Cys-Asn (3). We synthetically produced a molecule with this primary structure and compared the biological properties of this peptide with those of pure ST obtained by bacterial growth of strain 18D (biological ST).
MATERIALS AND METHODS Enterotoxin production. The ST peptide was synthesized by the solid-phase method (16, 27) with a Beckman model 990B peptide synthesizer. The complete procedure for synthesis and purification will be described in detail elsewhere. Briefly, for each synthesis, 1.00 g (0.53 meq) of benzhydryl amine resin and the following side-chain protecting groups were used: 0-(0-bromobenzyoxycarbonyl) for tyrosine, O-benzyl for threonine, serine for glutamic acid, and S-methoxybenzyl for cysteine. Protected amino acids were recrystallized from appropriate solvents to give single spots by thin-layer chromatography. All couplings were carried out with a 10-fold excess of protected amino acid plus dicyclohexylcarbodiimide. For asparagine, an equal molar amount of N-hydroxy benzotriazole was added to the protected amino acid, and dimethyl formamide was used as the solvent. All coupling reactions were >99% complete by the picric acid test (14) . The protected peptide polymers were treated with twice their weight of anisole, an equal weight of pyridine (7) After oxidation of the sulfhydryl groups to form the disulfide bonds, there remained no free sulfhydryl groups. The formation of the disulfide bonds necessary to obtain material with biological activity required specific conditions. Comparison of the spectral properties (by using nuclear magnetic resonance spectroscopy, circular dichroism, and UV spectroscopy) of synthetic and biological ST is in progress to establish the precise identity of the disulfide linkages in each of these toxin preparations. These will be described in detail subsequently.
The crude product was purified by gel filtration and ion-exchange chromatography. Amino acid analysis, gel and paper electrophoresis, and other chromatographic data all indicated a homogeneous product. The overall yield was approximately 25% of the theoretical yield. Synthetic ST preparations prepared on five separate occasions were examined for biological potency and immunogenicity. All yielded the same response described in this report for the first preparation produced.
Biological ST was purified to homogeneity from culture filtrates of strain 18D by a modification (22) of the methods described by Staples et al. (31) . The amounts of toxins were based on their protein concentration, determined by the method of Lowry et al. (26) .
Assay of secretory potency. The ability of graded dosages of the toxins to cause secretion was tested in the suckling mouse and rat ligated ileal loop assays by published methods (10, 21) . One mouse unit (MU) in the suckling mouse assay is defined as that amount of toxin which yields an intestinal weight/carcass weight ratio of .0.083.
Production of hyperimmune antiserum. Hyperimmune antiserum to biological ST was raised in goats and rabbits as described previously (22) . Synthetic ST was coupled to porcine immunoglobulin G (PIG) by mixing ST to PIG at a molar ratio of 100:1 with a ratio by weight of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide to total conjugate protein of 2:1 in 0.1 M phosphate buffer (pH 7.0) for 18 h at 4°C. This conjugate contained 47% ST by weight and 98% ST by moles. The conjugated ST retained 73% of its antigenicity, determined by enzyme-linked immunosorbent assay (ELISA) with hyperimmune goat and rabbit antisera to biological ST in a previously described double-sandwich technique (22) . The conjugate thus contained 343 antigen units (derived by multiplying the percentage of ST present by weight times the percentage of its antigenicity) per mg of protein. Animals were immunized intramuscularly with Freund complete adjuvant for the primary immunization and Freund incomplete adjuvant for the booster immunization given 1 month later. Goats received 1,100 followed by 2,300 ST antigen units, and rabbits received 300 followed by 500 ST antigen units.
Immunization and challenge of rats. Weanling Sprague-Dawley rats were immunized with the synthetic ST-PIG conjugate by means of an intraperitoneal primary immunization of 350 ST antigen units given with Freund complete adjuvant, followed at 4-day intervals by two peroral booster immunizations containing 700 ST antigen units each, which were given 2 h after the peroral administration of cimetidine to ablate gastric acidity. The rats were challenged 5 days after the final booster by the instillation for 18 h into a single ligated ileal loop of concentrations which evoke maximum secretion in unimmunized rats: 5 ng of either synthetic or biological ST and 0.1 ml of a broth culture containing 109 viable organisms of ST-producing human E. coli Texas 452 (078:H12) per ml. Five unimmunized and three immunized rats were challenged with each test material. Values are expressed as the mean ± standard error of the mean percent reduced secretion in immunized rats as compared with that in unimmunized controls; in each instance, >50% reduced secretion represents a significant difference (P < 0.001) between the two groups, as determined by Student's t test for two independent means.
Antitoxin response to immunization. At the time of challenge, serum and mucosal washings were processed as described previously (23) 
RESULTS
Capacity to induce fluid secretion. Synthetic and biological ST were equally potent in their ability to induce fluid secretion in the suckling mouse assay (Fig. 1) and rat ligated ileal loops (Fig. 2) . The slight variations observed in the minimum effective dosages of the two toxins in each assay model were within the range of experimental variation, and in fact several subsequently prepared preparations of synthetic ST evoked an identical response to that of biological ST thetic ST was 70% that of biological ST (Fig. 3) , but the antigenicity of the toxins was identical when both were tested with hyperimmune antisera to synthetic ST.
To evaluate the neutralizing effect of hyperimmune antisera to either synthetic or biological ST on the secretory effect of the toxins in the suckling mouse assay, three mice for each datum point were given 100 ,ul intraintestinally containing 2 MU (twice the minimum effective dosage) of each toxin that had been incubated with the designated antiserum dilution for 3 h at 37°C (Fig. 4) . The number of MU neutralized by 1 ml of antiserum was derived by multiplying the projected antiserum dilution required to neutralize (i.e., yield a gut/carcass ratio of >0.083) the secretory effect times the 10-fold dilution factor times a factor of 2 to adjust for the 2 MU used. Hyperimmune antisera to each of the toxin preparations seroneutralized the secretory effect of synthetic and biological ST in the suckling mouse assay to the same approximate degree: 1 ml of hyperimmune rabbit antiserum to biological ST neutralized 160 MU of synthetic and 190 MU of biological ST, whereas 1 ml of goat hyperimmune antiserum to synthetic ST neutralized 220 MU of synthetic and 240 MU of biological ST. challenge with all types of ETEC strains, regardless of the toxin form they produce. However, the low yields of pure biological ST that can be obtained by the currently available tedious and cumbersome procedures for purification would make it difficult to produce such a cross-linked vaccine in any appreciable quantity. Our present finding that synthetically produced ST is immunologically similar to the same toxin derived from fermentation techniques indicates that the more readily produced synthetic peptide can be substituted for biological ST in the cross-linked vaccine.
The results of the present study show that immunization with a synthetically produced ST toxin whose structure is based on that of human ST provides protection against challenge with ST-producing ETEC strains of human origin. It remains to be established, however, that this specific toxin will provide an equal degree of protection against ST-producing strains from animal sources, such as porcine or bovine, which appear to be structurally heterogeneous (8, 17) . The evidence available suggests that such will prove to be the case. Frantz and Robertson have reported that hyperimmune antiserum to porcine ST cross-neutralizes ST derived from ETEC strains of porcine, bovine, and human origin (8) , and, in the case of LT, we have shown that immunization of rats with porcine LT provides uniform protection against multiple heterologous human LT-producing strains (20) , despite the fact that minor antigenic differences between porcine and human LT are recognized (9, 15 
